A national leader in lung disease and transplantation
Inova Advanced Lung Disease and Transplant Program, located on the campus of nationally top-ranked Inova Fairfax Hospital, is recognized for excellence and innovation. Inova transplant surgeons and lung specialists offer new hope to individuals dealing with serious life-threatening lung disease that once was considered untreatable.
We have performed more than 200 lung transplants over the last 10 years, and according to the most recent Scientific Registry for Transplant Recipients (SRTR) report, our one-month and one-year survival rates exceed the national average. Review our outcomes.
The DC area's first and only lung transplant program
Inova pioneered lung and lung-heart transplants in the Northern Virginia and Washington, DC, metro areas. The first lung transplant was performed at Inova Fairfax Hospital in 1991. Today Inova remains sole provider of the region's only lung transplant program, with patient survival statistics above the national average.
Read and watch videos of our patients' stories
Specialized care for advanced lung disease
Inova's advanced lung disease clinics provide highly specialized evaluation and treatment for serious conditions. Our clinical experts continually seek out and implement the latest treatment techniques. These advancements may delay or forestall the need for a lung transplant or offer treatment options to patients not eligible for transplantation.
Participating in national efforts to accredit PH centers
Inova is one of six pilot sites collaborating with the national Pulmonary Hypertension Association to establish an accreditation program for PH centers across the country. Pulmonary hypertension is a rare and complex disease, requiring a high level of expertise to diagnosis, treat and manage. Learn more about Inova's role
A partner in national research efforts
Inova Advanced Lung Disease and Transplant Program is actively participating in state-of-the-art research studies pursuing more effective treatment for lung conditions. Our prestigious collaboration with the National Institutes of Health will further help develop new therapies for pulmonary hypertension, serious asthma and other lung disease. Learn more about the current research
Learn more about our world-class program